Key result
COSPRI protocol tests whether a novel diagnostic package reduces time to diagnosis in suspected CCS.
Why the study?
To evaluate whether a novel diagnostic package can reduce time to diagnosis and improve risk assessment compared to standard investigation in symptomatic chronic CAD.
Does a novel diagnostic package reduce waiting time to diagnosis compared to standard investigation in patients with suspected chronic coronary syndrome referred from primary care?
RCT (n=500)
Open-label
Cluster randomized
Yes
Does a novel diagnostic package reduce waiting time to diagnosis compared to standard investigation in patients with suspected chronic coronary syndrome referred from primary care?
This study protocol describes a cluster randomized trial evaluating a novel diagnostic imaging package versus standard exercise testing for suspected chronic coronary syndrome in primary care.
Answers are grounded in this paper and cite their sources.
RCT will test novel package for suspected CCS; leaves open whether it shortens time to diagnosis versus standard care.
BACKGROUND: This trial aims to assess the effectiveness of a novel diagnostic package in the investigation of symptomatic chronic coronary artery disease (CAD), with a focus on reducing the time to diagnosis and improving risk assessment, compared to the current standard investigation approach. The package investigation is comprised of combined single photon emission computed tomography (SPECT), echocardiography, coronary artery calcification (CAC) scoring, not previously evaluated in Sweden for individual cardiovascular prevention, and CadScore, an acoustic risk score. The standard investigation is comprised of exercise bicycle stress testing and echocardiography. METHODS: The trial involves patients with a pre-test probability > 15% for significant CAD referred from primary healthcare centers (PHCs) in Region Östergötland (population 471,241 in March 2023) in south-east Sweden. All the 47 PHCs of the region will be invited to participate and will, after approval, be cluster randomized into two groups: package investigation versus standard investigation. The primary outcome is a composite measure comprised of waiting time to invasive coronary angiography or communication of non-invasive myocardial ischemia investigation results. Secondary outcomes include major adverse cardiovascular events (MACE), cost per patient, signs of reversible ischemia on any test, radiation exposure, and adherence to prescribed cardioprotective drugs. DISCUSSION: This trial addresses the urgent problem of chest pain and dyspnea assessment in primary care and aims to speed up diagnosis, reduce the need for specialist consultations, and potentially improve patient outcomes, with referral to SPECT directly from PHC in comparison with the widely used exercise test. The novel approach includes CAC scoring. Additionally, the utility of acoustic CadScore in reclassifying the risk of CAD is explored. TRIAL REGISTRATION: The trial was registered on March 11, 2023, at ClinicalTrials.gov with the identifier: NCT05782582.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (2025) conducted an RCT in Suspected chronic coronary syndrome (n=500). Diagnostic package (SPECT, echocardiography, CAC scoring, and CadScore) vs. Standard investigation (exercise bicycle stress test and echocardiography) was evaluated on Waiting time to invasive coronary angiography or communication of non-invasive myocardial ischemia investigation results. The COSPRI trial is a study protocol designed to evaluate whether a novel diagnostic package reduces the time to diagnosis compared to standard investigation in patients with suspected chronic coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: